Tuck:
I don't often resent someone like I resent Mr. Dr. Pres., R&D at MEDI.
If you look hard enough, you can find immunogenicity for most (all?) human or humanized antibodies. In this case, I believe that MEDI has not only looked hard, but is also using related verbiage to "face save".
They are finally, IMO, going to test the antibody as it should have been tested....... at doses that do not deplete T cells apart from those exposed to antigen in the course of ongoing autoimmunity.
Hand waving! At least three years and many millions, wasted. Will MEDI look this hard for (non-neutralizing) antibody responses to vitaxin?
If they find (non-neutralizing) antibodies to vitaxin, will they (1) go out of their way to publicize their presence, (2) posture that FDA gives a damn, and (3) redesign trials to do an antibody run-around?
No!!!!!!!!!!
This just extends a long-standing issue at MEDI, IMO....... communications are designed to hide deficiencies re. R&D foresight and management.
What will happen if the new trials, at non-depleting doses, are successful? Mr. Dr. Pres., R&D will claim that he discovered a wonderful new route for using 507. Bet on it.
Rick |
